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After nerve injury maladaptive changes can occur in injured sensory neurons and along the entire nociceptive
pathway within the CNS, which may lead to spontaneous pain or pain hypersensitivity. The resulting neuro-
pathic pain syndromes present as a complex combination of negative and positive symptoms, which vary
enormously from individual to individual. This variation depends on a diversity of underlying pathophysiolog-
ical changes resulting from the convergence of etiological, genotypic, and environmental factors. The pain
phenotype can serve therefore, as a window on underlying pathophysiological neural mechanisms and as
a guide for developing personalized pain medicine.Introduction
Nociceptive pain reflects our capacity to detect the presence of
potentially damaging stimuli; it is an essential early warning
mechanism (Basbaum et al., 2009; Woolf and Ma, 2007). This
sensation is mediated in the periphery by high threshold primary
sensory neurons, the nociceptors, which transmit information via
nociceptive pathways in the spinal cord to the brain (Figure 1).
Following peripheral tissue injury or inflammation, reversible
adaptive changes in the sensory nervous system lead to the
generation of pain hypersensitivity, a protective mechanism
that ensures proper healing of damaged tissue. In contrast, in
neuropathic pain, the nervous system itself is injured and
changes in its sensitivity can become persistent—pain can occur
spontaneously, its threshold may fall dramatically such that
innocuous stimuli produce pain, and the duration and amplitude
of its response to noxious stimuli are amplified. Because these
neural changes in susceptible individuals can be irreversible,
neuropathic pain, once established, should be regarded as an
autonomous disease state of the nervous system in its own right.
Most patients do not develop neuropathic pain after nerve injury
(Kehlet et al., 2006) and although only a handful of genetic poly-
morphisms have been identified that confer either an enhanced
susceptibility to development of neuropathic pain, it is neverthe-
less clear that genotype is a substantial contributor (Binder et al.,
2011; Costigan et al., 2010; Lacroix-Fralish and Mogil, 2009;
Nissenbaum et al., 2010).
Neuropathic pain is common, greatly impairs quality of life,
and has a high economic impact on society: the Institute ofMedi-
cine reports that at least 116 million American adults suffer from
chronic pain and estimates for people suffering from neuropathic
pain are as high as 17.9% (Toth et al., 2009). Comorbidities such
as poor sleep, depression, and anxiety are common in neuro-
pathic pain patients, leading to unresolved arguments about
whether pain causes mood and sleep changes or whether indi-
viduals with mood and sleep disorders are at a higher risk of
developing pain (Turk et al., 2010). What is clear though is that
neuropathic pain is a major health problem. The first step in638 Neuron 73, February 23, 2012 ª2012 Elsevier Inc.the clinical diagnosis of neuropathic pain is to document the
disease or lesion that is presumed to have caused it, and its
anatomical site. Until very recently, this was also the end of the
diagnostic process, and often no attempt was made to identify
the actual neural mechanisms responsible for the generation of
the individual pain phenotype and how they may inform treat-
ment decisions. A common assumption is that a single etiology
causes neuropathic pain in a uniformway. However, neuropathic
pain is very heterogeneous, with multiple patterns of presenta-
tion reflecting diverse combinations of etiological, genetic and
environmental factors, and specifically, the neurobiological
processes they engage (Figure 2). Because of their mechanistic
diversity and different manifestations, these processes produce
a complex profile or constellation of positive and negative
sensory symptoms and signs, a ‘‘pain fingerprint’’ (Baron et al.,
2009; Mahn et al., 2011; Scholz et al., 2009). It is essential to shift
focus from etiology to the reaction of the nervous system to the
etiological pathology—to viewing neuropathic pain as amanifes-
tation of pathological neural plasticity. The advantage of this
approach is that it will lead to an explicit dual therapeutic focus
aimed both at etiological factors and the forms of maladaptive
plasticity they initiate.
Sensory Nerve Damage Produces Negative Symptoms
By definition, neuropathic pain involves damage to the nervous
system (Jensen et al., 2011). Often, negative symptoms are the
first indication of damage to the somatosensory system and
can be detected by quantitative sensory testing aswell as clinical
examination and to a more limited extent, history/questionnaire.
The cause of negative symptoms in peripheral neuropathies is
direct insult to primary sensory neurons. This may produce cell
death or compromise transduction (due to terminal atrophy) or
conduction (due to loss of peripheral axons) or transmission
(due to loss of central terminals) of sensory information. Loss of
function can manifest across the whole sensory spectrum (e.g.,
global numbness after a traumatic nerve injury) or it can affect
specific modalities (Freeman, 2009). For example, an elevated
Figure 1. The Nociceptive Pain Circuit
High-threshold nociceptors are activated by intense mechanical, thermal, or chemical stimuli and feed this information to nociceptive neurons in the spinal cord,
which project via the thalamus to cortical areas generating the sensory and emotional qualities of pain. These spinal cord pathways are subject to descending
inhibitory and facilitatory influences from the brainstem. Normally, activity in low-threshold afferents is carried by independent peripheral and central pathways
and only generates innocuous sensations.
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a common early manifestation of peripheral diabetic neuropathy
(Said, 2007) and in chemotherapy-induced neuropathies, where
sensory but not motor axons show mitochondrial damage
leading to hypoesthesia (Xiao et al., 2011). Many patients with
neural damage only have negative symptoms, some though,
also have positive symptoms because particular pathological
processes are engaged that increase pain sensitivity or drive
spontaneous activation of the nociceptive pathway.
Peripheral Sensitization after Nerve Lesions Increases
Pain Sensitivity
Peripheral sensitization most characteristically occurs after
peripheral inflammation and comprises a reduction in threshold
and an increase in the excitability of the peripheral terminals of
nociceptors in response to sensitizing inflammatory mediators.
This results in innocuous stimuli at the site of inflammation,
such as light touch, warm or cool temperatures, being perceived
as painful (allodynia), and stimuli that usually are felt as uncom-
fortable or slightly painful, such as a pinprick, becoming
extremely painful (hyperalgesia) in the primary area of inflamma-
tion. However, peripheral sensitization can also occur after nerve
lesions in the presence (peripheral neuritis) and absence of tissue
inflammation, and thereby can contribute to pain hypersensitivity
within the innervation zone of an affected nerve (Figure 3).
External mechanical, thermal, and chemical stimuli are con-
verted into voltage changes in sensory neurons by ion channels
that respond to specific environmental stimuli. After nerve injury,
peripheral sensitization results from reduced thresholds for acti-
vation these transducer channels together with nerve injury
induced changes in sodium and potassium channels. The best
characterized transducer ion channel is the nonselective cation
channel TRPV1, which has a well established role in peripheral
inflammatory pain (Huang et al., 2006). However, after nervedamage, posttranslational changes, trafficking, and expression
changes of TRPV1 also occur. After partial nerve injury, TRPV1
is upregulated in uninjured sensory fibers (Hudson et al., 2001;
Kim et al., 2008), and during diabetic neuropathy changes in
the expression of TRPV1 correlate with development of thermal
hyper- and hypoalgesia. In addition, TRPV1 begins to be ex-
pressed in large myelinated A-fibers (Hong and Wiley, 2005;
Pabbidi et al., 2008), one of several injury-induced phenotypic
shifts in low-threshold sensory neurons. Inhibiting TRPV1 activity
or decreasing TRPV1 levels reduces neuropathic hyperalgesia
(Christoph et al., 2006; Watabiki et al., 2011), and heat hyperal-
gesia after peripheral neuropathy induced by chemotherapeutic
agents is absent in TRPV1 knockout mice (Ta et al., 2010). Other
ion channels such as TRPA1, TRPM8, or P2X3 may also be
altered during nerve injury and contribute to neuropathic pain
hypersensitivity, but the potential contributions of these ion
channels to neuropathic pain are not well understood (Eid
et al., 2008; Shinoda et al., 2007; Xu et al., 2011).
TRPV1 is also expressed in sensory nerve axons of peripheral
nerves, not only at its peripheral terminal (Weller et al., 2011).
Because TRPV1 activation threshold is modified by inflamma-
tory mediators from immune cells, and injured nerves contain
many macrophages and T cells (Gaudet et al., 2011), it is quite
possible, therefore, that axonal TRPV1, just like peripheral
terminal TRPV1, may also become sensitized. Theoretically,
a reduction in TRPV1 thermal threshold to levels close to body
temperature along the axon could then lead to depolarization
and generation of action potentials, producing spontaneous
pain (Hoffmann et al., 2008).
While TRPV1 is an attractive target for treating neuropathic
pain, an unexpected obstacle for the therapeutic use of TRPV1
antagonists is the significant increase in body temperature
they produce (Swanson et al., 2005), as well as the risk of
damage due to loss of the warning heat pain signal. TheseNeuron 73, February 23, 2012 ª2012 Elsevier Inc. 639
Figure 2. From Etiology to Neuropathic Pain
The neuropathic syndrome is the end result of an initiating disease combined with individual contributing factors, such as genotype and environmental factors like
diet and life style, all of which lead to individual combinations of pathophysiological mechanisms, manifesting as an individual neuropathic pain phenotype.
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sites independent of temperature activation (Szallasi et al., 2007;
Watabiki et al., 2011). A second possibility is to modulate TRPV1
activation threshold by inhibiting kinases known to target TRPV1,
such as p38 and PKCε, which are under investigation in neuro-
pathic pain clinical trials and show some efficacy (Anand et al.,
2011). Also, repeated low-dose applications of the TRPV1
agonist capsaicin desensitize the channel through phosphoryla-
tion and Ca2+-dependent mechanisms (Touska et al., 2011).
However, a single application of extremely high concentrations
leads to atrophy of peripheral terminals, most likely due to an
overload of intracellular calcium and depolarization of mitochon-
drial membrane potential, which explains pain relief lasting up to
12 weeks after high-dose capsaicin treatments (Anand and Bley,
2011). As one would expect however, this treatment may be very
painful initially. Whether such terminal atrophy, which is a feature
of many forms of peripheral neuropathy, may itself lead to neuro-
pathic pain in susceptible individuals is something to consider.
After nerve injury, increased levels of neurotrophins, particu-
larly nerve growth factor (NGF), and cytokines are found at the
site of and distal to the injury (Dogrul et al., 2011; Gaudet et al.,
2011; Leung and Cahill, 2010). The neurotrophins activate
kinases, which alter expression, posttranslational modification
and trafficking of TRPV1 and voltage gated sodium channels
(Dib-Hajj et al., 2010; Mantyh et al., 2011). Furthermore, expres-
sion of voltage-gated potassium channels is decreased by neu-
rotrophin receptor-mediated activation of PKMz (Zhang et al.,
2012). Sequestering antibodies against NGF are effective in
treating inflammatory pain (Lane et al., 2010). The preclinical
picture for anti-NGF treatment for neuropathic pain, however,
is mixed, and one potential concern is that while increased
NGF may lead to pain by sensitizing nociceptor neurons,
sequestering NGF may induce transcriptional changes and
even cell death in intact neurons if an ongoing supply of target-
derived NGF is required for maintenance of a specific differenti-
ated neuronal phenotype.
Ectopic Activity after Nerve Injury Generates
Spontaneous Pain
Pain occurring in the absence of any external stimulus is a debil-
itating consequence of peripheral nerve injury. It can, potentially640 Neuron 73, February 23, 2012 ª2012 Elsevier Inc.at least, originate as a result of spontaneous activity generated
anywhere along the nociceptive pathway. Most frequently
however, spontaneous sensations after peripheral nerve lesions
appear to be generated as a result of hyperexcitability in the
primary sensory neuron, leading to ectopic action potential
discharge at the site of injury and resultant neuroma, but also
at more proximal axonal sites, including the soma (Amir et al.,
2005). Ectopic activity is a major and in perhaps most cases
the exclusive driver of the spontaneous sensations that manifest
after nerve injury or lesions producing paresthesia, dysthesia,
and pain. The pain may be episodic or continuous, superficial,
or deep, and often has shock-like bursts and a burning quality,
all of which may reflect engagement of ectopic activity in
different fibers with different temporal patterns of firing, as well
as subsequent central changes. While many changes occur in
injured neurons, uninjured fibers neighboring injured ones in
partial nerve injuries can potentially also give rise to unevoked
afferent input and thereby painful sensations (Wu et al., 2002);
in fact, some evidence suggests that this may be a large source
of neuropathic ectopic activity (Djouhri et al., 2006). Changes in
the uninjured neurons may result from mediators generated by
injured axons, immune cells, denervated Schwann cells and
target tissue. Ectopic activity can also be generated by stimuli;
for example, mechanosensitivity of neuromas is well described.
Ectopic activity can also contribute to central sensitization, as
discussed below.
What drives a normally quiet sensory axon, designed only to
conduct action potentials, to begin to initiate action potentials?
Nerve injury drastically changes the expression, distribution,
and phosphorylation of many ion channels in sensory neurons
leading to changes in intrinsic membrane properties and the
generation of membrane potential oscillations resulting in
rhythmic firing bursts in the absence of a stimulus. Which ion
channels are modified as a direct or indirect consequence of
a nerve injury or lesion? As for most neurons, the membrane
potential in sensory neurons is largely determined by potassium
channels. The two-pore domain K+ channels TRESK (K2p18.1)
and TREK-2 (K2p10.1) represent approximately 85% of K
+ back-
ground current in DRG neurons (Dobler et al., 2007; Kang and
Kim, 2006) with TRESK being particularly highly expressed in
the DRG (Allen Brain Atlas). After injury, TRESK is downregulated
Figure 3. Peripheral Sensitization
Changes in the sensitivity of the peripheral terminals of nociceptors to stimuli can contribute to evoked pain. This can occur through inflammatory mediators
sensitizing signal transducer proteins, persistent activation of transducer proteins by endogenous agonists, inherited polymorphisms of transducer proteins, or
an increase in membrane excitability.
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neuronal membrane potential (Tulleuda et al., 2011). However,
reduction in potassium leak current cannot be the sole cause
of ectopic activity. Subthreshold membrane potential oscilla-
tions, largely carried by the persistent component of the sodium
current, INaP, are frequently seen in injured sensory neurons
and may be a major contributor to ectopic spike discharge
(Amir et al., 1999). Computer modeling and pharmacological
inhibition support the importance of INaP for spontaneous
activity in injured neurons (Kovalsky et al., 2009; Xie et al.,
2011), even if the specific molecular identity of the responsible
sodium channel remains uncertain. Most likely for injured
sensory neurons, this current is generated by non-inactivating
Nav1.3- and Nav1.6-mediated currents; but there is also
evidence that Nav1.9 is involved (Dib-Hajj et al., 2010; Enomoto
et al., 2007; Herzog et al., 2001). In addition, it is possible that the
persistent current is modified by changes in the expression of
auxiliary sodium channel b subunits in injured and uninjured
fibers, which may alter trafficking and kinetics (Pertin et al.,
2005; Zhao et al., 2011).
Membrane potential oscillations, spontaneous activity, and
neuropathic pain behavior have also been attributed to themixed
cation current Ih conducted by hyperpolarization-acivated cyclic
nucleotide-gated (HCN) channels. Large sensory neuronsmainly
express HCN1, while small sensory neurons predominantly
express HCN2 (Biel et al., 2009; Emery et al., 2011; Momin
et al., 2008; Moosmang et al., 2001). In rodent models of neuro-
pathic pain, low concentrations of the nonspecific HCN antago-nist ZD7288 strongly reduce pain behavior and spontaneous
firing in injured fibers (Chaplan et al., 2003; Lee et al., 2005). In
addition, sensory neuron-specific HCN2/ mice show hardly
any signs of neuropathic pain, whereas HCN1/ mice develop
almost typical pain behavior after partial nerve ligations (Emery
et al., 2011; Momin et al., 2008). The evidence for changes in
HCN protein and transcript levels after nerve injury are some-
what contradictory and may be explained by somatic versus
axonal compartmentalization (Chaplan et al., 2003; Jiang et al.,
2008). However, even if expression changes are minimal, alter-
ations in cAMP levels could contribute to modified Ih densities,
and it is conceivable that inhibitors that block adenyl cyclase
exert some of their analgesic action in neuropathic pain models
in the periphery by reducing HCN channel sensitization (Wang
et al., 2011). How does Ih contribute to generating ectopic
discharges? Because of activation by hyperpolarizing potentials,
HCN channels are also an important component for membrane
potential oscillations in various neuronal networks (Biel et al.,
2009). Especially in concert with low-threshold T-type calcium
channels, neurons can display repetitive firing patterns, where
hyperpolarization leads to activation of Ih, slowly depolarizing
the membrane potential until a Ca2+ spike carried by T-type
calcium channels is initiated, further depolarizing the potential
and triggering a series of Na2+ spikes. The depolarization inacti-
vates Ih until the train of action potentials is followed by a hyper-
polarizing overshoot, which opens HCN channels and the cycle
can repeat (Biel et al., 2009). This model also explains the
observed analgesic effect of peripherally applied T-typeNeuron 73, February 23, 2012 ª2012 Elsevier Inc. 641
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Dogrul et al., 2003).
Given their contribution to generator potentials in the periph-
eral terminal and action potentials in the axon, it is not surprising
that voltage-gated sodium channels (VGSC) have been a prime
target of investigation and therapeutic approaches for neuro-
pathic pain (Devor, 2006; Dib-Hajj et al., 2010). Nav1.8 is mainly
expressed by A- and C-fiber nociceptors, Nav1.9 is selective for
a subset of C-fibers, whereas Nav1.1 and Nav1.6 are found
mostly in nonnociceptive neurons (Fukuoka et al., 2008; Fukuoka
and Noguchi, 2011). Nav1.7 seems to be expressed universally
in all sensory neurons, but clearly plays an important role in no-
ciception, as indicated by various monogenetic disorders
affecting this channel, including gain of function mutations in
Nav1.7 that result in ectopic firing of C-fibers in the absence of
nerve injury and spontaneous pain conditions (Cox et al., 2006;
Dib-Hajj et al., 2010; Faber et al., 2011). Nav1.3 is usually only
expressed during development (Waxman et al., 1994); however,
nerve injury drastically changes this expression profile and
expression of Nav1.3 returns in adult sensory neurons (Fukuoka
et al., 2008; Waxman et al., 1994). Notably, Nav1.3 has fast
enough gating kinetics to contribute to depolarizing afterpoten-
tials and with that, to membrane potential oscillations (Devor,
2006). Levels of Nav1.6, Nav1.7, Nav1.8, and Nav1.9 are
decreased in the soma of injured neurons (Kim et al., 2002a).
However, an increase in axonal membrane expression of
Nav1.8, presumably due to trafficking and possibly axonal trans-
lation, is observed in injured sensory nerve fibers (Novakovic
et al., 1998; Thakor et al., 2009). The exact mechanism of this
change in sodium channel profiles is not well understood but
likely involves TNFa-mediated pathways (He et al., 2010; Scha¨-
fers et al., 2003). Interestingly, changes are not limited to injured
nerves, as re-expression of Nav1.3 and increased axonal levels
of Nav1.8 are also seen in neighboring undamaged fibers (Gold
et al., 2003; He et al., 2010) as well as in central nociceptive
pathways (Hains et al., 2003, 2004, 2005). Antisense oligodeox-
ynucleotides against Nav1.3 and Nav1.8 significantly reduce
neuropathic pain related symptoms (Hains et al., 2004; Lai
et al., 2002). However, nerve injury induces typical neuropathic
pain-like behavior in sensory neuron-specific conditional
Nav1.3, Nav1.7, or Nav1.8, knockout mice (Nassar et al., 2005,
2006). These conflicting data may reflect developmental
compensation of sodium channel expression, but this awaits
a definitive answer.
In addition to expression changes, sodium channels are also
targets of phosphorylation by various kinases during neuro-
pathic pain. Mainly triggered by proinflammatory cytokines after
nerve injury, mitogen-activated protein kinases (MAPK) may be
the predominant ones as they are highly expressed in painful
human neuromas and phosphorylate Nav1.3, Nav1.7, Nav1.8,
and Nav1.9 (Binshtok et al., 2008; Black et al., 2008; Dib-Hajj
et al., 2010; Hudmon et al., 2008; Stamboulian et al., 2010).
One prominent effect of such phosphorylation is a relief of
slow inactivation (Binshtok et al., 2008; Stamboulian et al.,
2010).
Voltage-gated sodium channels are prime targets for pharma-
ceutical intervention, as illustrated by the multiple sodium
channel blockers used to treat neuropathic pain, e.g., local anes-642 Neuron 73, February 23, 2012 ª2012 Elsevier Inc.thetics, mexilitine, and carbamazepine (Gracely et al., 1992).
However, the currently available nonselective blockers come at
the cost of cardiovascular and CNS side effects. Subtype-
specific or state-dependent inhibition of sodium channels is
a promising approach to treat the ectopic activity of neuropathic
pain (Binshtok et al., 2007; Jarvis et al., 2007), as well as kinase
inhibitors that prevent post-translational modifications in the
channels.
Voltage-gated potassium channels are also required for action
potential firing and are also involved in spontaneous trains of
action potentials after nerve injury. Low voltage-activated potas-
sium channels, which stabilize membrane potential and regulate
action potential number on depolarization, are downregulated by
nerve injury (Kim et al., 2002b; Rose et al., 2011). Here, particu-
larly KCNQ (Kv7) channels came into focus because of the anti-
nociceptive effect of the specific KCNQ opener retigabine in
animal models of neuropathic pain, although it has failed in clin-
ical trials (Blackburn-Munro and Jensen, 2003; Passmore et al.,
2003). On the other hand, nerve injury has little or no effect on the
expression of high voltage-activated potassium channels with
fast kinetics, which determine spike duration and are required
for fast firing (Kim et al., 2002b).
Ectopic activity offers several treatment opportunities.
Whether a particular channel is a more prominent driver of
ectopic activity in one individual versus another is not yet known;
however, would have important consequences for treatment
choice. Generally, treatment of spontaneous activity is likely to
be an important component of neuropathic pain treatment,
because it is a major contributor to spontaneous pain and to
central changes in the nociceptive pathway that amplify pain,
central sensitization.
Central Sensitization Amplifies Pain and Reduces
Threshold
Until the early 1980s, the presence, intensity, and duration of
pain, whatever its etiology, was thought to simply reflect the
degree and timing of nociceptor activation. According to this
view, a noxious stimulus was required to produce pain, but after
tissue injury peripheral sensitization could increase the sensi-
tivity of nociceptors in the inflamed region such that they re-
sponded to less intense innocuous stimuli, while after nerve
injury ectopic activity in nociceptors could generate sponta-
neous pain. The discovery of central sensitization, a form of
long-lasting synaptic plasticity in the dorsal horn triggered by
nociceptors that facilitates nociceptive processing (Woolf,
1983), has forced a profound change in the model. It led to the
realization that amplification of incoming signals within the
CNS has a very substantial role in the generation of clinical
pain hypersensitivity, including neuropathic pain. Indeed, central
sensitization has now provided a mechanistic explanation for
how low threshold A or C fibers can begin to produce pain,
why there is a spread of sensitivity beyond areas of tissue injury
or outside a damaged nerve territory, why repeated stimuli at
a fixed intensity can lead to a progressive increase in pain, and
why pain may long outlast a peripheral stimulus (Pfau et al.,
2011; Seal et al., 2009; Woolf, 2011). Furthermore, we now
appreciate that central sensitization in certain conditions,
including after nerve injury, can become autonomous.
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is typically induced by a burst of activity in nociceptors lasting
several tens of seconds, and includes establishment both of
homo- and heterosynaptic potentiation, the former sharing
many features of long term potentiation (LTP) in cortical neurons
(Latremoliere andWoolf, 2009; Ohnami et al., 2011; Ruscheweyh
et al., 2011). Unlike classic LTP, however, heterosynaptic facili-
tation is particularly prominent in central sensitization andmeans
that a nociceptor-specific conditioning input can enable subse-
quent long lasting facilitation of responses to inputs from
low-threshold A beta- or C-fibers, and to afferent inputs from
topographically quite different locations. This occurs by a spread
of the change in synaptic strength from activated to neighboring
non-activated synapses, as opposed to changes in LTP which
are usually restricted to a single dendritic spine coactivated by
two inputs. Heterosynaptic facilitation after brief nociceptor trig-
gering input can last for hours while homosynaptic LTP may last
longer. Mechanistically, central sensitization includes pre- and
postsynaptic changes as well as an increase in post synaptic
membrane excitability (Latremoliere and Woolf, 2009). As for
LTP, alterations in postsynaptic calcium levels are a major driver
in initiating change in synaptic strength: Calcium change can be
caused by calcium flux through ionotropic receptors and
voltage-gated calcium channels or by release from intracellular
stores on activation of metabotropic receptors or receptor tyro-
sine kinases (Cheng et al., 2010; Ohnami et al., 2011). Cav1.2
L-type calcium channels play important roles and can undergo
bidirectional regulation by miR-103 to initiate some forms of
central sensitization (Favereaux et al., 2011; Fossat et al.,
2010). Calcium-dependent intracellular signaling pathways
produce posttranslational and transcriptional changes in many
effector proteins, altering their levels, distribution, and functional
activity (Asiedu et al., 2011; Katano et al., 2011;Matsumura et al.,
2010; Miletic et al., 2011). The major players in the synaptic
changes underlying activity-dependent central sensitization are
the NMDA, AMPA, and mGluR glutamate receptors, the
substance P NK1 receptor, BDNF and its TrkB receptor, ephrinB
and EphBR, CaMKII, PKA, PKC, src, ERK and CREB, and Kv4.2
(D’Mello et al., 2011; Hu and Gereau, 2011; Latremoliere and
Woolf, 2009; Nozaki et al., 2011).
Central sensitization in normal individuals can only be initiated
by a conditioning nociceptor input, because these afferents cor-
elease glutamate and neuropeptides, providing greater opportu-
nity for sufficient postsynaptic calcium increase. After nerve
injury, however, Ab fibers can undergo phenotypic changes
including increased expression of neuropeptides (Nitzan-
Luques et al., 2011) such that they may acquire the capacity to
trigger or maintain central sensitization (Figure 4). More recently,
changes in dendritic spines in dorsal horn neurons mediated by
the monomeric G protein Rac1 have been detected after periph-
eral nerve injury, indicating that spinal circuitry may physically
change after nerve injury (Tan et al., 2011). In addition, it appears
that some individuals have a higher susceptibility, due to geno-
typic differences, in producing central sensitization, and there-
fore have a higher risk of neuropathic pain development or
persistence (Campbell et al., 2009; Tegeder et al., 2006, 2008).
While synaptic plasticity contributing to central sensitization
has been most extensively studied in the spinal cord, it is alsofound in other CNS regions, for example the anterior cingulate
gyrus, prefrontal cortex, amygdala, and periaqueductal gray (Li
et al., 2010; Ren et al., 2011).
Although central sensitization was originally considered
to represent an increase in excitatory synaptic strength and
neuronal excitability, it has become clear, particularly for neuro-
pathic pain, that a loss of inhibition in the dorsal horn also plays
an important role (Figure 5). Inhibiting GABA and glycine in the
spinal cord increases A-fiber-mediated excitatory transmission
in the superficial dorsal horn (Baba et al., 2003) and produces
tactile allodynia (Sivilotti and Woolf, 1994). Furthermore, partial
peripheral nerve injury results in a reduction of GABA-induced
IPSCs in the dorsal horn (Janssen et al., 2011; Moore et al.,
2002), at least a component of which appears to be due to an
excitotoxic loss of GABAergic interneurons (Scholz et al.,
2005). In addition, TNF-a reduces GABAergic interneuron
activity via p38 (Zhang et al., 2010), and increased calcium levels
in mitochondria drive reactive oxygen species production in
dorsal horn neurons leading to reduced GABA release (Kim
et al., 2011; Yowtak et al., 2011). The inhibitory effect of GABA
is further reduced as BDNF released from microglia after nerve
injury alters the anion reversal potential in some dorsal horn
neurons decreasing or even phase shifting GABA’s actions on
these neurons (Coull et al., 2005; Prescott et al., 2006). More-
over, production of other inhibitory substances, such as adeno-
sine, may be reduced after nerve damage (Sowa et al., 2010).
Loss of local segmental inhibition in the dorsal horn will be
exacerbated by loss of descending inhibitory controls from the
rostroventral medulla (De Felice et al., 2011). A loss of neurons
in this brainstem region after nerve injury indicates that injury-
induced apoptosis occurs at multiple neuraxial levels (Leong
et al., 2011).
Central sensitization provides, then, a mechanism whereby
normally subthreshold synaptic input is recruited into driving a
novel output from nociceptive neurons, reducing their threshold,
increasing receptive field size, and altering firing temporal
dynamics. All these changes contribute to the generation of
dynamic mechanical allodynia in response to low threshold
mechanoreceptor activation, pin prick or mechanical hyperalge-
sia and temporal summation. There is substantial opportunity for
therapeutic intervention in patients with manifestations of the
presence of central sensitization: a major driver of central sensi-
tization is ectopic activity originating from a damaged nerve.
Injection of a regional anesthetic to the injured nerve can lead
to a temporary reduction in allodynia and secondary hyperalge-
sia (Gracely et al., 1992). Similarly, a reduction in transmitter
release by blocking N-type calcium channels (Brittain et al.,
2011) or by interfering with calcium channel trafficking (Bauer
et al., 2009; Tran-Van-Minh and Dolphin, 2010), both reduce
central sensitization and are effective in the treatment of neuro-
pathic pain. Another widely used approach for treating neuro-
pathic pain are dual amine uptake inhibitors, such as duloxetine
and nortriptyline, which likely affect the noradrenergic descend-
ing inhibitory pathway (De Felice et al., 2011). Targeting specific
GABAA a-subunits to directly increase inhibitory input in the
spinal cord may also provide a novel treatment avenue (Knabl
et al., 2008). The NMDA receptor is also an attractive target
for reducing central sensitization (Woolf and Thompson, 1991),Neuron 73, February 23, 2012 ª2012 Elsevier Inc. 643
Figure 4. Central Sensitization
Changes in the spinal cord that lead to the strengthening of synaptic input from both nociceptor and low-threshold mechanoreceptors onto nociceptive neurons
contribute to an amplification of pain, with a reduction in its threshold, an expansion in its spatial extent, and a change in its temporal characteristics. The
recruitment of normally innocuous afferent inputs to the nociceptive pathway is an important aspect of central sensitization.
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NMDA receptor antagonists.
Activation of Immune Cells during Neuropathic Pain
Peripheral axonal injury results in a massive macrophage infiltra-
tion at the site of and distal to injury, as well as into the neuroma
and dorsal root ganglion, where they provide a rich source of
immune mediators that can act on sensory neurons (Figure 6). In644 Neuron 73, February 23, 2012 ª2012 Elsevier Inc.addition, substantialmicroglial activation isgenerated in thedorsal
horn of the spinal cord in close vicinity of the central terminals of
injured primary sensory neurons (Beggs and Salter, 2010; Tsuda
et al., 2003). The development of spinal microgliosis requires
both axonal injury and nociceptive afferent input (Hathway et al.,
2009; Suter et al., 2009). Following nerve injury, signaling mole-
cules released fromprimary afferents drivemicroglial chemotaxis,
proliferation and activation (Calvo et al., 2011; Calvo et al., 2010;
Figure 5. Spinal Disinhibition
Excitatory nociceptive signals are enhanced after nerve injury by a reduction in normal inhibitory regulation through a loss of local inhibitory interneurons,
a depolarized anion reversal potential and reduced descending inhibition.
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ReviewKawasaki et al., 2008). Inhibiting microglial activation after injury
reduces allodynia and hyperalgesia after nerve injury (Beggs and
Salter, 2010;Calvo andBennett, 2011) but it is not clear how these
microglial changes alter nociceptive transmission.
Adaptive immune cells are also found in the spinal cord after
peripheral nerve injury. After recruitment into the dorsal horn
from the circulating system, CD4+ T cells release cytokines,
such as interferon g, to activate microglia. Both, T cell-deficient
mice and interferon g knockout mice, show diminished mechan-
ical allodynia following acute nerve injury (Costigan et al., 2009;
Tsuda et al., 2009). It remains to be established what effect pre-
venting T cell recruitment into the CNSmay have on neuropathic
pain. Nevertheless, the contribution of peripheral immune cells
and microglia to the development of neuropathic pain offers
a novel potential treatment strategy, as immunosuppressive
drugs show some efficacy in animal models of nerve injury
even though they have no intrinsic analgesic activity (Orhan
et al., 2010; Scholz et al., 2008). However, it remains uncertain
if similar immune activation occurs in humans, and if so in what
conditions and to what extent. Certainly the effects of most treat-
ments targeted at microglia in preclinical studies appear to work
best soon after nerve injury, implying thatmicroglia are somehow
involved in establishing neuropathic pain, but perhaps not in its
maintenance.
CNS Plasticity after Nerve Injury
Neuronal plasticity during neuropathic pain is not limited to the
spinal cord and multiple changes are observed in response to
acute and chronic pain stimuli (Apkarian et al., 2011; Tracey,
2011). Functional neuroimaging has identified a network of brain
regions activated by experimental noxious stimuli (the so-called
‘‘pain matrix’’) that includes medial prefrontal cortex, nucleus
accumbens, anterior cingulate cortex, insula, amygdala, peria-queductal gray, locus coerulus, and rostrovental medulla. More
recent work is revealing changes in the resting state of the brain
in patients with spontaneous pain (Apkarian et al., 2011; Tracey,
2011). In addition to ‘‘traditional’’ CNS areas involved in pain pro-
cessing, the cerebellum may also be part of pain and general
aversive processing (Moulton et al., 2011). Brain regions acti-
vated during acute nociceptive pain differ from those activated
during chronic pain (Schweinhardt et al., 2006), and the same
pain areas are activated differently by an identical noxious stim-
ulus administered to healthy subjects compared to subjects with
chronic pain (Baliki et al., 2011). There are also documented
differences in the processing of spontaneous and evoked pain
(Friebel et al., 2011; Parks et al., 2011). The finding that functional
connectivity patterns during painful experiences are flexible and
context dependent (Ploner et al., 2011), underscores the
dynamic nature of the pain network.
Regional decreases in gray matter volume as detected by
magnetic resonance imaging-based volumetry have been re-
ported in several chronic pain cohorts (Apkarian et al., 2011).
However, these volume changes do not indicate neuronal
degeneration since they are reversible after successful pain
treatment (Gwilym et al., 2010), and their nature and significance
remain uncertain, although they may be a useful biomarker.
Interestingly, no significant regional gray matter volume change
was detected, in chronic non neuropathic facial pain, whereas in
patients with trigeminal neuralgia, the gray matter was reduced
in the primary somatosensory cortex, anterior insula, putamen,
nucleus accumbens, and the thalamus and increased in the
posterior insula (Gustin et al., 2011). This suggests that the path-
ogenesis of neuropathic and nonneuropathic pain conditions
maybe fundamentally different. Furthermore, when comparing
different neuropathic disorders, different gray matter density
changes were observed (Baliki et al., 2011), which may indicateNeuron 73, February 23, 2012 ª2012 Elsevier Inc. 645
Figure 6. Immune Contribution to Neuropathic Pain
Innate and adaptive immune cells in the periphery and spinal cord can sensitize primary nociceptors and secondary nociceptive neurons respectively to produce
pain hypersensitivity.
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Reviewthat CNS changes detected by imaging reflect the individual pain
phenotype. Certainly relating individual pain response to indi-
vidual imaging signals may help link pain phenotype to pain
genotype (Tracey, 2011). In a clinical research setting at least,
brain imaging should become a very useful component of phe-
notyping pain patients, thereby helping assess the mechanisms
present in individual patients and how they manifest.From Pain Phenotype to Individualized Analgesic
Treatment
Clinicians encounter neuropathic pain patients with diverse
genetic and environmental backgrounds and various degrees
of nerve damage, all of which contribute to a complex combina-
tion of neural pathophysiological mechanisms, which in turn
manifest as the individual pain phenotype. As typically only
30% of patients respond to even the gold standard FDA
approved treatments (Finnerup et al., 2010), identification of
the pattern of mechanisms present in an individual should be
a useful approach for identifying patients more likely to respond
to a particular treatment and establishing individualized pain
treatment. The pattern of expression of pain-related sensory646 Neuron 73, February 23, 2012 ª2012 Elsevier Inc.abnormalities, the individual sensory phenotype, should reveal
clues of the underlying pathophysiological dysfunction.
Since one specific symptom (e.g., burning pain) may be gener-
ated by several different underlying pathophysiological mecha-
nisms (e.g., peripheral sensitization, gain of function mutations
in Nav1.7, or ectopic activity due to alteration in HCN2), it is
more likely that a specific constellation of many sensory symp-
toms and signs might better predict underlying mechanisms.
Patient reported outcomes, as well as quantitative sensory
testing, or a combination of both, are beginning to be used to
analyze sensory profiles in neuropathic pain patients and distinct
subgroups of patients can be detected who are characterized by
different specific sensory profiles (Baron et al., 2009; Bouhassira
et al., 2005; Scholz et al., 2009).
In a large group of patients with diabetic peripheral neuropathy
and postherpetic neuralgia, a sensory profiling approach re-
vealed five subgroups of patients with distinct pain-related
sensory phenotypes (Baron et al., 2009). For example, patients
who suffer from considerable burning pain and paresthesias
but minimal mechanical allodynia and thermal hyperalgesia
and who additionally show numbness as a prominent finding
probably have sensory terminal deafferentation in the skin with
Figure 7. Individual Pathophysiology Requires Personalized Treatment
Etiology, genotype, and environmental factors lead to individual pathophysiological changes and individual neuropathic pain profiles. Precise clinical examination
and diagnostic tools are a prerequisite to define the pain phenotype and then to use this to identify personalized treatment options.
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or atrophy of sensory terminals innervating the extremities
together with ectopic activity in heat nociceptors, best explains
these findings. Patients with spontaneous burning pain in combi-
nation with dynamic mechanical allodynia and minimal negative
symptoms (no reduced thermal threshold), reflects the presence
of relatively preserved and sensitized nociceptors in the skin
together with central sensitization (Baron et al., 2009). A major
goal is to identify the most relevant and discriminatory aspects
of the pain phenotype that most robustly reflect different mech-
anisms or combinations of mechanisms.
Given that it is possible then to identify subgroups of neuro-
pathic pain patients with distinct sensory phenotypes, does a
particular treatment perform better in one sensory profile
subgroup of patients than another, and is this because of the
different neural mechanisms engaged in the subgroup? Several
encouraging trials indicate that this is likely. Following intracuta-
neous botulinum toxin, for example, better pain reduction corre-
lates with the relative preservation of cutaneous innervation, as
documented by normal thermal thresholds (Ranoux et al.,
2008). On the contrary, the response to systemic opioids corre-
lates with a loss of peripheral terminals and a higher heat pain
threshold (Edwards et al., 2006). Furthermore, lidocaine
produces better results in patients with mechanical allodynia at
baseline, than in those who did not have this symptom (Attal
et al., 2004; Finnerup et al., 2002). An exploratory post-hoc anal-
ysis within a negative pregabalin trial for painful HIV-neuropathy
has revealed that only a subgroup of patients with pinprick
hyperalgesia, presumably indicative of central sensitization,
showed a significant response to pregabalin (Simpson et al.,
2010). If pregabalin works by reducing transmitter release and
thereby central sensitization, identifying patients in whom central
sensitization plays a role in pain generation can identify patients
who respond better to the drug.
Personalized pain treatment is in its infancy, but the advances
both in the understanding of pathophysiological mechanisms in
the somatosensory system that can occur after neural damage,
and in defining the individual pain phenotype, promise to trans-form diagnosis, from disease to mechanism, and treatment,
from empirical to evidence-based (Figure 7). Whether an etiolog-
ical factor, such as nerve injury, or a disease like diabetes, results
in pain will depend on its interaction with genotypic poly-
morphisms and environmental factors. These interactions will
produce particular maladaptive changes in the nervous system
that manifest as spontaneous pain or pain hypersensitivity. The
ability to infer presence of specific pathophysiological mecha-
nisms from the pain phenotype will vastly improve treatment
choice.
ACKNOWLEDGMENTS
The authors are supported by the NIH NS038253, NS058870 (C.J.W.), IMI
European collaboration (R.B.), and NS747313 (C.A.v.H.). Conflict of interest
(R.B.): Astra Zeneca, Esteve, Pfizer, Genzyme, Gru¨nenthal, Mundipharma,
Allergan, Sanofi Pasteur, Medtronic, Eisai, UCB BioSciences, Lilly, Boehringer
Ingelheim, Astellas, Novartis, Bristol-Myers Squibb.
REFERENCES
Amir, R., Michaelis, M., and Devor, M. (1999). Membrane potential oscillations
in dorsal root ganglion neurons: role in normal electrogenesis and neuropathic
pain. J. Neurosci. 19, 8589–8596.
Amir, R., Kocsis, J.D., and Devor, M. (2005). Multiple interacting sites of
ectopic spike electrogenesis in primary sensory neurons. J. Neurosci. 25,
2576–2585.
Anand, P., and Bley, K. (2011). Topical capsaicin for pain management: ther-
apeutic potential and mechanisms of action of the new high-concentration
capsaicin 8% patch. Br. J. Anaesth. 107, 490–502.
Anand, P., Shenoy, R., Palmer, J.E., Baines, A.J., Lai, R.Y., Robertson, J., Bird,
N., Ostenfeld, T., and Chizh, B.A. (2011). Clinical trial of the p38 MAP kinase
inhibitor dilmapimod in neuropathic pain following nerve injury. Eur. J. Pain
15, 1040–1048.
Apkarian, A.V., Hashmi, J.A., and Baliki, M.N. (2011). Pain and the brain: spec-
ificity and plasticity of the brain in clinical chronic pain. Pain 152 (3, Suppl),
S49–S64.
Asiedu, M.N., Tillu, D.V., Melemedjian, O.K., Shy, A., Sanoja, R., Bodell, B.,
Ghosh, S., Porreca, F., and Price, T.J. (2011). Spinal protein kinase M z under-
lies the maintenance mechanism of persistent nociceptive sensitization. J.
Neurosci. 31, 6646–6653.Neuron 73, February 23, 2012 ª2012 Elsevier Inc. 647
Neuron
ReviewAttal, N., Rouaud, J., Brasseur, L., Chauvin, M., and Bouhassira, D. (2004).
Systemic lidocaine in pain due to peripheral nerve injury and predictors of
response. Neurology 62, 218–225.
Baba, H., Ji, R.R., Kohno, T., Moore, K.A., Ataka, T., Wakai, A., Okamoto, M.,
and Woolf, C.J. (2003). Removal of GABAergic inhibition facilitates polysyn-
aptic A fiber-mediated excitatory transmission to the superficial spinal dorsal
horn. Mol. Cell. Neurosci. 24, 818–830.
Baliki, M.N., Schnitzer, T.J., Bauer, W.R., and Apkarian, A.V. (2011). Brain
morphological signatures for chronic pain. PLoS ONE 6, e26010.
Baron, R., To¨lle, T.R., Gockel, U., Brosz, M., and Freynhagen, R. (2009). A
cross-sectional cohort survey in 2100 patients with painful diabetic neurop-
athy and postherpetic neuralgia: differences in demographic data and sensory
symptoms. Pain 146, 34–40.
Barton, M.E., Eberle, E.L., and Shannon, H.E. (2005). The antihyperalgesic
effects of the T-type calcium channel blockers ethosuximide, trimethadione,
and mibefradil. Eur. J. Pharmacol. 521, 79–85.
Basbaum, A.I., Bautista, D.M., Scherrer, G., and Julius, D. (2009). Cellular and
molecular mechanisms of pain. Cell 139, 267–284.
Bauer, C.S., Nieto-Rostro, M., Rahman, W., Tran-Van-Minh, A., Ferron, L.,
Douglas, L., Kadurin, I., Sri Ranjan, Y., Fernandez-Alacid, L., Millar, N.S.,
et al. (2009). The increased trafficking of the calcium channel subunit alpha2-
delta-1 to presynaptic terminals in neuropathic pain is inhibited by the alpha2-
delta ligand pregabalin. J. Neurosci. 29, 4076–4088.
Beggs, S., and Salter, M.W. (2010). Microglia-neuronal signalling in neuro-
pathic pain hypersensitivity 2.0. Curr. Opin. Neurobiol. 20, 474–480.
Biel, M., Wahl-Schott, C., Michalakis, S., and Zong, X. (2009). Hyperpolariza-
tion-activated cation channels: from genes to function. Physiol. Rev. 89,
847–885.
Binder, A., May, D., Baron, R., Maier, C., To¨lle, T.R., Treede, R.D., Berthele, A.,
Faltraco, F., Flor, H., Gierthmu¨hlen, J., et al. (2011). Transient receptor poten-
tial channel polymorphisms are associated with the somatosensory function in
neuropathic pain patients. PLoS ONE 6, e17387.
Binshtok, A.M., Bean, B.P., andWoolf, C.J. (2007). Inhibition of nociceptors by
TRPV1-mediated entry of impermeant sodium channel blockers. Nature 449,
607–610.
Binshtok, A.M., Wang, H., Zimmermann, K., Amaya, F., Vardeh, D., Shi, L.,
Brenner, G.J., Ji, R.R., Bean, B.P., Woolf, C.J., and Samad, T.A. (2008). Noci-
ceptors are interleukin-1beta sensors. J. Neurosci. 28, 14062–14073.
Black, J.A., Nikolajsen, L., Kroner, K., Jensen, T.S., and Waxman, S.G. (2008).
Multiple sodium channel isoforms and mitogen-activated protein kinases are
present in painful human neuromas. Ann. Neurol. 64, 644–653.
Blackburn-Munro, G., and Jensen, B.S. (2003). The anticonvulsant retigabine
attenuates nociceptive behaviours in rat models of persistent and neuropathic
pain. Eur. J. Pharmacol. 460, 109–116.
Bouhassira, D., Attal, N., Alchaar, H., Boureau, F., Brochet, B., Bruxelle, J.,
Cunin, G., Fermanian, J., Ginies, P., Grun-Overdyking, A., et al. (2005).
Comparison of pain syndromes associated with nervous or somatic lesions
and development of a new neuropathic pain diagnostic questionnaire (DN4).
Pain 114, 29–36.
Brittain, J.M., Duarte, D.B., Wilson, S.M., Zhu, W., Ballard, C., Johnson, P.L.,
Liu, N., Xiong, W., Ripsch, M.S., Wang, Y., et al. (2011). Suppression of inflam-
matory and neuropathic pain by uncoupling CRMP-2 from the presynaptic
Ca2+ channel complex. Nat. Med. 17, 822–829.
Calvo, M., and Bennett, D.L. (2011). The mechanisms of microgliosis and pain
following peripheral nerve injury. Exp. Neurol., in press. Published online
August 26, 2011. 10.1016/j.expneurol.2011.08.018.
Calvo, M., Zhu, N., Tsantoulas, C., Ma, Z., Grist, J., Loeb, J.A., and Bennett,
D.L. (2010). Neuregulin-ErbB signaling promotes microglial proliferation and
chemotaxis contributing to microgliosis and pain after peripheral nerve injury.
J. Neurosci. 30, 5437–5450.
Calvo, M., Zhu, N., Grist, J., Ma, Z., Loeb, J.A., and Bennett, D.L. (2011).
Following nerve injury neuregulin-1 drives microglial proliferation and neuro-
pathic pain via the MEK/ERK pathway. Glia 59, 554–568.648 Neuron 73, February 23, 2012 ª2012 Elsevier Inc.Campbell, C.M., Edwards, R.R., Carmona, C., Uhart, M., Wand, G., Carteret,
A., Kim, Y.K., Frost, J., and Campbell, J.N. (2009). Polymorphisms in the
GTP cyclohydrolase gene (GCH1) are associated with ratings of capsaicin
pain. Pain 141, 114–118.
Chaplan, S.R., Guo, H.Q., Lee, D.H., Luo, L., Liu, C., Kuei, C., Velumian, A.A.,
Butler, M.P., Brown, S.M., and Dubin, A.E. (2003). Neuronal hyperpolarization-
activated pacemaker channels drive neuropathic pain. J. Neurosci. 23, 1169–
1178.
Cheng, L.Z., Lu¨, N., Zhang, Y.Q., and Zhao, Z.Q. (2010). Ryanodine receptors
contribute to the induction of nociceptive input-evoked long-term potentiation
in the rat spinal cord slice. Mol. Pain 6, 1.
Christoph, T., Gru¨nweller, A., Mika, J., Scha¨fer, M.K., Wade, E.J., Weihe, E.,
Erdmann, V.A., Frank, R., Gillen, C., and Kurreck, J. (2006). Silencing of vanil-
loid receptor TRPV1 by RNAi reduces neuropathic and visceral pain in vivo.
Biochem. Biophys. Res. Commun. 350, 238–243.
Costigan, M., Moss, A., Latremoliere, A., Johnston, C., Verma-Gandhu, M.,
Herbert, T.A., Barrett, L., Brenner, G.J., Vardeh, D., Woolf, C.J., and Fitzgerald,
M. (2009). T-cell infiltration and signaling in the adult dorsal spinal cord is
a major contributor to neuropathic pain-like hypersensitivity. J. Neurosci. 29,
14415–14422.
Costigan, M., Belfer, I., Griffin, R.S., Dai, F., Barrett, L.B., Coppola, G., Wu, T.,
Kiselycznyk, C., Poddar, M., Lu, Y., et al. (2010). Multiple chronic pain states
are associated with a common amino acid-changing allele in KCNS1. Brain
133, 2519–2527.
Coull, J.A., Beggs, S., Boudreau, D., Boivin, D., Tsuda, M., Inoue, K., Gravel,
C., Salter, M.W., and De Koninck, Y. (2005). BDNF from microglia causes
the shift in neuronal anion gradient underlying neuropathic pain. Nature 438,
1017–1021.
Cox, J.J., Reimann, F., Nicholas, A.K., Thornton, G., Roberts, E., Springell, K.,
Karbani, G., Jafri, H., Mannan, J., Raashid, Y., et al. (2006). An SCN9A chan-
nelopathy causes congenital inability to experience pain. Nature 444, 894–898.
D’Mello, R., Marchand, F., Pezet, S., McMahon, S.B., and Dickenson, A.H.
(2011). Perturbing PSD-95 interactions with NR2B-subtype receptors attenu-
ates spinal nociceptive plasticity and neuropathic pain. Mol. Ther. 19, 1780–
1792.
De Felice, M., Sanoja, R., Wang, R., Vera-Portocarrero, L., Oyarzo, J., King, T.,
Ossipov, M.H., Vanderah, T.W., Lai, J., Dussor, G.O., et al. (2011). Engage-
ment of descending inhibition from the rostral ventromedial medulla protects
against chronic neuropathic pain. Pain 152, 2701–2709.
Devor, M. (2006). Sodium channels and mechanisms of neuropathic pain. J.
Pain 7 (Suppl 1 ), S3–S12.
Dib-Hajj, S.D., Cummins, T.R., Black, J.A., and Waxman, S.G. (2010). Sodium
channels in normal and pathological pain. Annu. Rev. Neurosci. 33, 325–347.
Djouhri, L., Koutsikou, S., Fang, X., McMullan, S., and Lawson, S.N. (2006).
Spontaneous pain, both neuropathic and inflammatory, is related to frequency
of spontaneous firing in intact C-fiber nociceptors. J. Neurosci. 26, 1281–1292.
Dobler, T., Springauf, A., Tovornik, S., Weber, M., Schmitt, A., Sedlmeier, R.,
Wischmeyer, E., and Do¨ring, F. (2007). TRESK two-pore-domain K+ channels
constitute a significant component of background potassium currents in
murine dorsal root ganglion neurones. J. Physiol. 585, 867–879.
Dogrul, A., Gardell, L.R., Ossipov, M.H., Tulunay, F.C., Lai, J., and Porreca, F.
(2003). Reversal of experimental neuropathic pain by T-type calcium channel
blockers. Pain 105, 159–168.
Dogrul, A., Gul, H., Yesilyurt, O., Ulas, U.H., and Yildiz, O. (2011). Systemic and
spinal administration of etanercept, a tumor necrosis factor alpha inhibitor,
blocks tactile allodynia in diabetic mice. Acta Diabetol. 48, 135–142.
Edwards, R.R., Haythornthwaite, J.A., Tella, P., Max, M.B., and Raja, S. (2006).
Basal heat pain thresholds predict opioid analgesia in patients with posther-
petic neuralgia. Anesthesiology 104, 1243–1248.
Eid, S.R., Crown, E.D., Moore, E.L., Liang, H.A., Choong, K.C., Dima, S.,
Henze, D.A., Kane, S.A., and Urban, M.O. (2008). HC-030031, a TRPA1 selec-
tive antagonist, attenuates inflammatory- and neuropathy-induced mechan-
ical hypersensitivity. Mol. Pain 4, 48.
Neuron
ReviewEmery, E.C., Young, G.T., Berrocoso, E.M., Chen, L., and McNaughton, P.A.
(2011). HCN2 ion channels play a central role in inflammatory and neuropathic
pain. Science 333, 1462–1466.
Enomoto, A., Han, J.M., Hsiao, C.F., and Chandler, S.H. (2007). Sodium
currents in mesencephalic trigeminal neurons fromNav1.6 null mice. J. Neuro-
physiol. 98, 710–719.
Faber, C.G., Hoeijmakers, J.G., Ahn, H.S., Cheng, X., Han, C., Choi, J.S., Es-
tacion, M., Lauria, G., Vanhoutte, E.K., Gerrits, M.M., et al. (2011). Gain of func-
tion Na(V) 1.7 mutations in idiopathic small fiber neuropathy. Ann Neurol. 71,
26–39.
Favereaux, A., Thoumine, O., Bouali-Benazzouz, R., Roques, V., Papon, M.A.,
Salam, S.A., Drutel, G., Le´ger, C., Calas, A., Nagy, F., and Landry, M. (2011).
Bidirectional integrative regulation of Cav1.2 calcium channel by microRNA
miR-103: role in pain. EMBO J. 30, 3830–3841.
Finnerup, N.B., Sindrup, S.H., Bach, F.W., Johannesen, I.L., and Jensen, T.S.
(2002). Lamotrigine in spinal cord injury pain: a randomized controlled trial.
Pain 96, 375–383.
Finnerup, N.B., Sindrup, S.H., and Jensen, T.S. (2010). The evidence for phar-
macological treatment of neuropathic pain. Pain 150, 573–581.
Fossat, P., Dobremez, E., Bouali-Benazzouz, R., Favereaux, A., Bertrand, S.S.,
Kilk, K., Le´ger, C., Cazalets, J.R., Langel, U., Landry, M., and Nagy, F. (2010).
Knockdown of L calcium channel subtypes: differential effects in neuropathic
pain. J. Neurosci. 30, 1073–1085.
Freeman, R. (2009). Not all neuropathy in diabetes is of diabetic etiology: differ-
ential diagnosis of diabetic neuropathy. Curr. Diab. Rep. 9, 423–431.
Friebel, U., Eickhoff, S.B., and Lotze, M. (2011). Coordinate-based meta-anal-
ysis of experimentally induced and chronic persistent neuropathic pain. Neu-
roimage 58, 1070–1080.
Fukuoka, T., and Noguchi, K. (2011). Comparative study of voltage-gated
sodium channel a-subunits in non-overlapping four neuronal populations in
the rat dorsal root ganglion. Neurosci. Res. 70, 164–171.
Fukuoka, T., Kobayashi, K., Yamanaka, H., Obata, K., Dai, Y., and Noguchi, K.
(2008). Comparative study of the distribution of the alpha-subunits of voltage-
gated sodium channels in normal and axotomized rat dorsal root ganglion
neurons. J. Comp. Neurol. 510, 188–206.
Gaudet, A.D., Popovich, P.G., and Ramer, M.S. (2011). Wallerian degenera-
tion: gaining perspective on inflammatory events after peripheral nerve injury.
J. Neuroinflammation 8, 110.
Gold, M.S., Weinreich, D., Kim, C.S., Wang, R., Treanor, J., Porreca, F., and
Lai, J. (2003). Redistribution of Na(V)1.8 in uninjured axons enables neuro-
pathic pain. J. Neurosci. 23, 158–166.
Gracely, R.H., Lynch, S.A., and Bennett, G.J. (1992). Painful neuropathy:
altered central processing maintained dynamically by peripheral input. Pain
51, 175–194.
Gustin, S.M., Peck, C.C., Wilcox, S.L., Nash, P.G., Murray, G.M., and Hender-
son, L.A. (2011). Different pain, different brain: thalamic anatomy in neuro-
pathic and non-neuropathic chronic pain syndromes. J. Neurosci. 31, 5956–
5964.
Gwilym, S.E., Filippini, N., Douaud, G., Carr, A.J., and Tracey, I. (2010).
Thalamic atrophy associated with painful osteoarthritis of the hip is reversible
after arthroplasty: a longitudinal voxel-based morphometric study. Arthritis
Rheum. 62, 2930–2940.
Hains, B.C., Klein, J.P., Saab, C.Y., Craner, M.J., Black, J.A., and Waxman,
S.G. (2003). Upregulation of sodium channel Nav1.3 and functional involve-
ment in neuronal hyperexcitability associated with central neuropathic pain
after spinal cord injury. J. Neurosci. 23, 8881–8892.
Hains, B.C., Saab, C.Y., Klein, J.P., Craner, M.J., and Waxman, S.G. (2004).
Altered sodium channel expression in second-order spinal sensory neurons
contributes to pain after peripheral nerve injury. J. Neurosci. 24, 4832–4839.
Hains, B.C., Saab, C.Y., and Waxman, S.G. (2005). Changes in electrophysio-
logical properties and sodium channel Nav1.3 expression in thalamic neurons
after spinal cord injury. Brain 128, 2359–2371.Hathway, G.J., Vega-Avelaira, D., Moss, A., Ingram, R., and Fitzgerald, M.
(2009). Brief, low frequency stimulation of rat peripheral C-fibres evokes pro-
longed microglial-induced central sensitization in adults but not in neonates.
Pain 144, 110–118.
He, X.H., Zang, Y., Chen, X., Pang, R.P., Xu, J.T., Zhou, X., Wei, X.H., Li, Y.Y.,
Xin, W.J., Qin, Z.H., and Liu, X.G. (2010). TNF-a contributes to up-regulation of
Nav1.3 and Nav1.8 in DRG neurons following motor fiber injury. Pain 151,
266–279.
Herzog, R.I., Cummins, T.R., and Waxman, S.G. (2001). Persistent TTX-resis-
tant Na+ current affects resting potential and response to depolarization in
simulated spinal sensory neurons. J. Neurophysiol. 86, 1351–1364.
Hoffmann, T., Sauer, S.K., Horch, R.E., and Reeh, P.W. (2008). Sensory trans-
duction in peripheral nerve axons elicits ectopic action potentials. J. Neurosci.
28, 6281–6284.
Hong, S., and Wiley, J.W. (2005). Early painful diabetic neuropathy is associ-
ated with differential changes in the expression and function of vanilloid
receptor 1. J. Biol. Chem. 280, 618–627.
Hu, H.J., and Gereau, R.W., 4th. (2011). Metabotropic glutamate receptor 5
regulates excitability and Kv4.2-containing K+ channels primarily in excitatory
neurons of the spinal dorsal horn. J. Neurophysiol. 105, 3010–3021.
Huang, J., Zhang, X., and McNaughton, P.A. (2006). Modulation of tempera-
ture-sensitive TRP channels. Semin. Cell Dev. Biol. 17, 638–645.
Hudmon, A., Choi, J.S., Tyrrell, L., Black, J.A., Rush, A.M., Waxman, S.G., and
Dib-Hajj, S.D. (2008). Phosphorylation of sodium channel Na(v)1.8 by p38
mitogen-activated protein kinase increases current density in dorsal root
ganglion neurons. J. Neurosci. 28, 3190–3201.
Hudson, L.J., Bevan, S., Wotherspoon, G., Gentry, C., Fox, A., and Winter, J.
(2001). VR1 protein expression increases in undamaged DRG neurons after
partial nerve injury. Eur. J. Neurosci. 13, 2105–2114.
Janssen, S.P., Truin, M., Van Kleef, M., and Joosten, E.A. (2011). Differential
GABAergic disinhibition during the development of painful peripheral neurop-
athy. Neuroscience 184, 183–194.
Jarvis, M.F., Honore, P., Shieh, C.C., Chapman, M., Joshi, S., Zhang, X.F.,
Kort, M., Carroll, W., Marron, B., Atkinson, R., et al. (2007). A-803467, a potent
and selective Nav1.8 sodium channel blocker, attenuates neuropathic and
inflammatory pain in the rat. Proc. Natl. Acad. Sci. USA 104, 8520–8525.
Jensen, T.S., Baron, R., Haanpa¨a¨, M., Kalso, E., Loeser, J.D., Rice, A.S., and
Treede, R.D. (2011). A newdefinition of neuropathic pain. Pain152, 2204–2205.
Jiang, Y.Q., Xing, G.G., Wang, S.L., Tu, H.Y., Chi, Y.N., Li, J., Liu, F.Y., Han,
J.S., and Wan, Y. (2008). Axonal accumulation of hyperpolarization-activated
cyclic nucleotide-gated cation channels contributes to mechanical allodynia
after peripheral nerve injury in rat. Pain 137, 495–506.
Kang, D., and Kim, D. (2006). TREK-2 (K2P10.1) and TRESK (K2P18.1) are
major background K+ channels in dorsal root ganglion neurons. Am. J. Physiol.
Cell Physiol. 291, C138–C146.
Katano, T., Nakazawa, T., Nakatsuka, T., Watanabe, M., Yamamoto, T., and
Ito, S. (2011). Involvement of spinal phosphorylation cascade of Tyr1472-
NR2B, Thr286-CaMKII, and Ser831-GluR1 in neuropathic pain. Neuropharma-
cology 60, 609–616.
Kawasaki, Y., Xu, Z.Z., Wang, X., Park, J.Y., Zhuang, Z.Y., Tan, P.H., Gao, Y.J.,
Roy, K., Corfas, G., Lo, E.H., and Ji, R.R. (2008). Distinct roles of matrix metal-
loproteases in the early- and late-phase development of neuropathic pain. Nat.
Med. 14, 331–336.
Kehlet, H., Jensen, T.S., and Woolf, C.J. (2006). Persistent postsurgical pain:
risk factors and prevention. Lancet 367, 1618–1625.
Kim, C.H., Oh, Y., Chung, J.M., and Chung, K. (2002a). Changes in three
subtypes of tetrodotoxin sensitive sodium channel expression in the axotom-
ized dorsal root ganglion in the rat. Neurosci. Lett. 323, 125–128.
Kim, D.S., Choi, J.O., Rim, H.D., and Cho, H.J. (2002b). Downregulation of
voltage-gated potassium channel alpha gene expression in dorsal root ganglia
following chronic constriction injury of the rat sciatic nerve. Brain Res. Mol.
Brain Res. 105, 146–152.Neuron 73, February 23, 2012 ª2012 Elsevier Inc. 649
Neuron
ReviewKim, H.Y., Park, C.K., Cho, I.H., Jung, S.J., Kim, J.S., and Oh, S.B. (2008).
Differential Changes in TRPV1 expression after trigeminal sensory nerve injury.
J. Pain 9, 280–288.
Kim, H.Y., Lee, K.Y., Lu, Y., Wang, J., Cui, L., Kim, S.J., Chung, J.M., and
Chung, K. (2011). Mitochondrial Ca(2+) uptake is essential for synaptic plas-
ticity in pain. J. Neurosci. 31, 12982–12991.
Knabl, J., Witschi, R., Ho¨sl, K., Reinold, H., Zeilhofer, U.B., Ahmadi, S., Brock-
haus, J., Sergejeva, M., Hess, A., Brune, K., et al. (2008). Reversal of patholog-
ical pain through specific spinal GABAA receptor subtypes. Nature 451,
330–334.
Kovalsky, Y., Amir, R., and Devor, M. (2009). Simulation in sensory neurons
reveals a key role for delayed Na+ current in subthreshold oscillations and
ectopic discharge: implications for neuropathic pain. J. Neurophysiol. 102,
1430–1442.
Lacroix-Fralish, M.L., and Mogil, J.S. (2009). Progress in genetic studies of
pain and analgesia. Annu. Rev. Pharmacol. Toxicol. 49, 97–121.
Lai, J., Gold, M.S., Kim, C.S., Bian, D., Ossipov, M.H., Hunter, J.C., and Por-
reca, F. (2002). Inhibition of neuropathic pain by decreased expression of the
tetrodotoxin-resistant sodium channel, NaV1.8. Pain 95, 143–152.
Lane, N.E., Schnitzer, T.J., Birbara, C.A., Mokhtarani, M., Shelton, D.L., Smith,
M.D., and Brown, M.T. (2010). Tanezumab for the treatment of pain from oste-
oarthritis of the knee. N. Engl. J. Med. 363, 1521–1531.
Latremoliere, A., and Woolf, C.J. (2009). Central sensitization: a generator of
pain hypersensitivity by central neural plasticity. J. Pain 10, 895–926.
Lee, D.H., Chang, L., Sorkin, L.S., and Chaplan, S.R. (2005). Hyperpolariza-
tion-activated, cation-nonselective, cyclic nucleotide-modulated channel
blockade alleviates mechanical allodynia and suppresses ectopic discharge
in spinal nerve ligated rats. J. Pain 6, 417–424.
Leong, M.L., Gu, M., Speltz-Paiz, R., Stahura, E.I., Mottey, N., Steer, C.J., and
Wessendorf, M. (2011). Neuronal loss in the rostral ventromedial medulla in
a rat model of neuropathic pain. J. Neurosci. 31, 17028–17039.
Leung, L., and Cahill, C.M. (2010). TNF-alpha and neuropathic pain—a review.
J. Neuroinflammation 7, 27.
Li, X.Y., Ko, H.G., Chen, T., Descalzi, G., Koga, K., Wang, H., Kim, S.S., Shang,
Y., Kwak, C., Park, S.W., et al. (2010). Alleviating neuropathic pain hypersen-
sitivity by inhibiting PKMzeta in the anterior cingulate cortex. Science 330,
1400–1404.
Mahn, F., Hu¨llemann, P., Gockel, U., Brosz, M., Freynhagen, R., To¨lle, T.R.,
and Baron, R. (2011). Sensory symptom profiles and co-morbidities in painful
radiculopathy. PLoS ONE 6, e18018.
Mantyh, P.W., Koltzenburg, M., Mendell, L.M., Tive, L., and Shelton, D.L.
(2011). Antagonism of nerve growth factor-TrkA signaling and the relief of
pain. Anesthesiology 115, 189–204.
Matsumura, S., Kunori, S., Mabuchi, T., Katano, T., Nakazawa, T., Abe, T., Wa-
tanabe, M., Yamamoto, T., Okuda-Ashitaka, E., and Ito, S. (2010). Impairment
of CaMKII activation and attenuation of neuropathic pain in mice lacking NR2B
phosphorylated at Tyr1472. Eur. J. Neurosci. 32, 798–810.
Miletic, G., Sullivan, K.M., Dodson, A.M., Lippitt, J.A., Schneider, J.A., and
Miletic, V. (2011). Changes in calcineurin message, enzyme activity and
protein content in the spinal dorsal horn are associated with chronic constric-
tion injury of the rat sciatic nerve. Neuroscience 188, 142–147.
Momin, A., Cadiou, H., Mason, A., and McNaughton, P.A. (2008). Role of the
hyperpolarization-activated current Ih in somatosensory neurons. J. Physiol.
586, 5911–5929.
Moore, K.A., Kohno, T., Karchewski, L.A., Scholz, J., Baba, H., andWoolf, C.J.
(2002). Partial peripheral nerve injury promotes a selective loss of GABAergic
inhibition in the superficial dorsal horn of the spinal cord. J. Neurosci. 22, 6724–
6731.
Moosmang, S., Stieber, J., Zong, X., Biel, M., Hofmann, F., and Ludwig, A.
(2001). Cellular expression and functional characterization of four hyperpolar-
ization-activated pacemaker channels in cardiac and neuronal tissues. Eur. J.
Biochem./FEBS 268, 1646–1652.650 Neuron 73, February 23, 2012 ª2012 Elsevier Inc.Moulton, E.A., Elman, I., Pendse, G., Schmahmann, J., Becerra, L., and Bor-
sook, D. (2011). Aversion-related circuitry in the cerebellum: responses to
noxious heat and unpleasant images. J. Neurosci. 31, 3795–3804.
Nassar, M.A., Levato, A., Stirling, L.C., and Wood, J.N. (2005). Neuropathic
pain develops normally in mice lacking both Na(v)1.7 and Na(v)1.8. Mol. Pain
1, 24.
Nassar, M.A., Baker, M.D., Levato, A., Ingram, R., Mallucci, G., McMahon,
S.B., andWood, J.N. (2006). Nerve injury induces robust allodynia and ectopic
discharges in Nav1.3 null mutant mice. Mol. Pain 2, 33.
Nissenbaum, J., Devor, M., Seltzer, Z., Gebauer, M., Michaelis, M., Tal, M.,
Dorfman, R., Abitbul-Yarkoni, M., Lu, Y., Elahipanah, T., et al. (2010). Suscep-
tibility to chronic pain following nerve injury is genetically affected by CACNG2.
Genome Res. 20, 1180–1190.
Nitzan-Luques, A., Devor, M., and Tal, M. (2011). Genotype-selective pheno-
typic switch in primary afferent neurons contributes to neuropathic pain.
Pain 152, 2413–2426.
Novakovic, S.D., Tzoumaka, E., McGivern, J.G., Haraguchi, M., Sangames-
waran, L., Gogas, K.R., Eglen, R.M., and Hunter, J.C. (1998). Distribution of
the tetrodotoxin-resistant sodium channel PN3 in rat sensory neurons in
normal and neuropathic conditions. J. Neurosci. 18, 2174–2187.
Nozaki, C., Vergnano, A.M., Filliol, D., Ouagazzal, A.M., Le Goff, A., Carvalho,
S., Reiss, D., Gaveriaux-Ruff, C., Neyton, J., Paoletti, P., and Kieffer, B.L.
(2011). Zinc alleviates pain through high-affinity binding to the NMDA receptor
NR2A subunit. Nat. Neurosci. 14, 1017–1022.
Ohnami, S., Tanabe, M., Shinohara, S., Takasu, K., Kato, A., and Ono, H.
(2011). Role of voltage-dependent calcium channel subtypes in spinal long-
term potentiation of C-fiber-evoked field potentials. Pain 152, 623–631.
Orhan, C.E., Onal, A., and Ulker, S. (2010). Antihyperalgesic and antiallodynic
effect of sirolimus in neuropathic pain and the role of cytokines in this effect.
Neurosci. Lett. 481, 17–20.
Pabbidi, R.M., Yu, S.Q., Peng, S., Khardori, R., Pauza, M.E., and Premkumar,
L.S. (2008). Influence of TRPV1 on diabetes-induced alterations in thermal pain
sensitivity. Mol. Pain 4, 9.
Parks, E.L., Geha, P.Y., Baliki, M.N., Katz, J., Schnitzer, T.J., and Apkarian,
A.V. (2011). Brain activity for chronic knee osteoarthritis: dissociating evoked
pain from spontaneous pain. Eur. J. Pain 15, 843.e1–e14.
Passmore, G.M., Selyanko, A.A., Mistry, M., Al-Qatari, M., Marsh, S.J.,
Matthews, E.A., Dickenson, A.H., Brown, T.A., Burbidge, S.A., Main, M., and
Brown, D.A. (2003). KCNQ/M currents in sensory neurons: significance for
pain therapy. J. Neurosci. 23, 7227–7236.
Pertin, M., Ji, R.R., Berta, T., Powell, A.J., Karchewski, L., Tate, S.N., Isom,
L.L., Woolf, C.J., Gilliard, N., Spahn, D.R., and Decosterd, I. (2005). Upregula-
tion of the voltage-gated sodium channel beta2 subunit in neuropathic pain
models: characterization of expression in injured and non-injured primary
sensory neurons. J. Neurosci. 25, 10970–10980.
Pfau, D.B., Klein, T., Putzer, D., Pogatzki-Zahn, E.M., Treede, R.D., and Ma-
gerl, W. (2011). Analysis of hyperalgesia time courses in humans after painful
electrical high-frequency stimulation identifies a possible transition from early
to late LTP-like pain plasticity. Pain 152, 1532–1539.
Ploner, M., Lee, M.C., Wiech, K., Bingel, U., and Tracey, I. (2011). Flexible
cerebral connectivity patterns subserve contextual modulations of pain.
Cereb. Cortex 21, 719–726.
Prescott, S.A., Sejnowski, T.J., and De Koninck, Y. (2006). Reduction of anion
reversal potential subverts the inhibitory control of firing rate in spinal lamina I
neurons: towards a biophysical basis for neuropathic pain. Mol. Pain 2, 32.
Ranoux, D., Attal, N., Morain, F., and Bouhassira, D. (2008). Botulinum toxin
type A induces direct analgesic effects in chronic neuropathic pain. Ann. Neu-
rol. 64, 274–283.
Ren, W., Palazzo, E., Maione, S., and Neugebauer, V. (2011). Differential
effects of mGluR7 and mGluR8 activation on pain-related synaptic activity in
the amygdala. Neuropharmacology 61, 1334–1344.
Neuron
ReviewRose, K., Ooi, L., Dalle, C., Robertson, B., Wood, I.C., and Gamper, N. (2011).
Transcriptional repression of the M channel subunit Kv7.2 in chronic nerve
injury. Pain 152, 742–754.
Ruscheweyh, R., Wilder-Smith, O., Drdla, R., Liu, X.G., and Sandku¨hler, J.
(2011). Long-term potentiation in spinal nociceptive pathways as a novel target
for pain therapy. Mol. Pain 7, 20.
Said, G. (2007). Diabetic neuropathy—a review. Nat. Clin. Pract. Neurol. 3,
331–340.
Scha¨fers, M., Lee, D.H., Brors, D., Yaksh, T.L., and Sorkin, L.S. (2003).
Increased sensitivity of injured and adjacent uninjured rat primary sensory
neurons to exogenous tumor necrosis factor-alpha after spinal nerve ligation.
J. Neurosci. 23, 3028–3038.
Scholz, J., Broom, D.C., Youn, D.H., Mills, C.D., Kohno, T., Suter, M.R., Moore,
K.A., Decosterd, I., Coggeshall, R.E., andWoolf, C.J. (2005). Blocking caspase
activity prevents transsynaptic neuronal apoptosis and the loss of inhibition in
lamina II of the dorsal horn after peripheral nerve injury. J. Neurosci. 25, 7317–
7323.
Scholz, J., Abele, A., Marian, C., Ha¨ussler, A., Herbert, T.A., Woolf, C.J., and
Tegeder, I. (2008). Low-dose methotrexate reduces peripheral nerve injury-
evoked spinal microglial activation and neuropathic pain behavior in rats.
Pain 138, 130–142.
Scholz, J., Mannion, R.J., Hord, D.E., Griffin, R.S., Rawal, B., Zheng, H., Scoff-
ings, D., Phillips, A., Guo, J., Laing, R.J., et al. (2009). A novel tool for the
assessment of pain: validation in low back pain. PLoS Med. 6, e1000047.
Schweinhardt, P., Glynn, C., Brooks, J., McQuay, H., Jack, T., Chessell, I.,
Bountra, C., and Tracey, I. (2006). An fMRI study of cerebral processing of
brush-evoked allodynia in neuropathic pain patients. Neuroimage 32, 256–
265.
Seal, R.P., Wang, X., Guan, Y., Raja, S.N., Woodbury, C.J., Basbaum, A.I., and
Edwards, R.H. (2009). Injury-induced mechanical hypersensitivity requires C-
low threshold mechanoreceptors. Nature 462, 651–655.
Shinoda,M., Kawashima, K., Ozaki, N., Asai, H., Nagamine, K., and Sugiura, Y.
(2007). P2X3 receptor mediates heat hyperalgesia in a rat model of trigeminal
neuropathic pain. J. Pain 8, 588–597.
Simpson, D.M., Schifitto, G., Clifford, D.B., Murphy, T.K., Durso-De Cruz, E.,
Glue, P., Whalen, E., Emir, B., Scott, G.N., and Freeman, R.; 1066 HIV Neurop-
athyStudyGroup. (2010). Pregabalin for painful HIV neuropathy: a randomized,
double-blind, placebo-controlled trial. Neurology 74, 413–420.
Sivilotti, L., and Woolf, C.J. (1994). The contribution of GABAA and glycine
receptors to central sensitization: disinhibition and touch-evoked allodynia in
the spinal cord. J. Neurophysiol. 72, 169–179.
Sowa, N.A., Taylor-Blake, B., and Zylka, M.J. (2010). Ecto-50-nucleotidase
(CD73) inhibits nociception by hydrolyzing AMP to adenosine in nociceptive
circuits. J. Neurosci. 30, 2235–2244.
Stamboulian, S., Choi, J.S., Ahn, H.S., Chang, Y.W., Tyrrell, L., Black, J.A.,
Waxman, S.G., and Dib-Hajj, S.D. (2010). ERK1/2 mitogen-activated protein
kinase phosphorylates sodium channel Na(v)1.7 and alters its gating proper-
ties. J. Neurosci. 30, 1637–1647.
Suter, M.R., Berta, T., Gao, Y.J., Decosterd, I., and Ji, R.R. (2009). Large A-
fiber activity is required for microglial proliferation and p38 MAPK activation
in the spinal cord: different effects of resiniferatoxin and bupivacaine on spinal
microglial changes after spared nerve injury. Mol. Pain 5, 53.
Swanson, D.M., Dubin, A.E., Shah, C., Nasser, N., Chang, L., Dax, S.L., Jetter,
M., Breitenbucher, J.G., Liu, C., Mazur, C., et al. (2005). Identification and bio-
logical evaluation of 4-(3-trifluoromethylpyridin-2-yl)piperazine-1-carboxylic
acid (5-trifluoromethylpyridin-2-yl)amide, a high affinity TRPV1 (VR1) vanilloid
receptor antagonist. J. Med. Chem. 48, 1857–1872.
Szallasi, A., Cortright, D.N., Blum, C.A., and Eid, S.R. (2007). The vanilloid
receptor TRPV1: 10 years from channel cloning to antagonist proof-of-
concept. Nat. Rev. Drug Discov. 6, 357–372.
Ta, L.E., Bieber, A.J., Carlton, S.M., Loprinzi, C.L., Low, P.A., and Windebank,
A.J. (2010). Transient Receptor Potential Vanilloid 1 is essential for cisplatin-
induced heat hyperalgesia in mice. Mol. Pain 6, 15.Tan, A.M., Chang, Y.W., Zhao, P., Hains, B.C., and Waxman, S.G. (2011).
Rac1-regulated dendritic spine remodeling contributes to neuropathic pain
after peripheral nerve injury. Exp. Neurol. 232, 222–233.
Tegeder, I., Costigan, M., Griffin, R.S., Abele, A., Belfer, I., Schmidt, H., Ehnert,
C., Nejim, J., Marian, C., Scholz, J., et al. (2006). GTP cyclohydrolase and tet-
rahydrobiopterin regulate pain sensitivity and persistence. Nat. Med. 12,
1269–1277.
Tegeder, I., Adolph, J., Schmidt, H., Woolf, C.J., Geisslinger, G., and Lo¨tsch, J.
(2008). Reduced hyperalgesia in homozygous carriers of a GTP cyclohydro-
lase 1 haplotype. Eur. J. Pain 12, 1069–1077.
Thakor, D.K., Lin, A., Matsuka, Y., Meyer, E.M., Ruangsri, S., Nishimura, I., and
Spigelman, I. (2009). Increased peripheral nerve excitability and local NaV1.8
mRNA up-regulation in painful neuropathy. Mol. Pain 5, 14.
Toth, C., Lander, J., and Wiebe, S. (2009). The prevalence and impact of
chronic pain with neuropathic pain symptoms in the general population. Pain
Med. 10, 918–929.
Touska, F., Marsakova, L., Teisinger, J., and Vlachova, V. (2011). A ‘‘cute’’
desensitization of TRPV1. Curr. Pharm. Biotechnol. 12, 122–129.
Tracey, I. (2011). Can neuroimaging studies identify pain endophenotypes in
humans? Nat. Rev. Neurol. 7, 173–181.
Tran-Van-Minh, A., and Dolphin, A.C. (2010). The alpha2delta ligand gabapen-
tin inhibits the Rab11-dependent recycling of the calcium channel subunit al-
pha2delta-2. J. Neurosci. 30, 12856–12867.
Tsuda, M., Shigemoto-Mogami, Y., Koizumi, S., Mizokoshi, A., Kohsaka, S.,
Salter, M.W., and Inoue, K. (2003). P2X4 receptors induced in spinal microglia
gate tactile allodynia after nerve injury. Nature 424, 778–783.
Tsuda, M., Masuda, T., Kitano, J., Shimoyama, H., Tozaki-Saitoh, H., and In-
oue, K. (2009). IFN-gamma receptor signaling mediates spinal microglia acti-
vation driving neuropathic pain. Proc. Natl. Acad. Sci. USA 106, 8032–8037.
Tulleuda, A., Cokic, B., Callejo, G., Saiani, B., Serra, J., and Gasull, X. (2011).
TRESK channel contribution to nociceptive sensory neurons excitability:
modulation by nerve injury. Mol. Pain 7, 30.
Turk, D.C., Audette, J., Levy, R.M., Mackey, S.C., and Stanos, S. (2010).
Assessment and treatment of psychosocial comorbidities in patients with
neuropathic pain. Mayo Clin. Proc. Suppl. 85, S42–S50.
Wang, H., Xu, H., Wu, L.J., Kim, S.S., Chen, T., Koga, K., Descalzi, G., Gong,
B., Vadakkan, K.I., Zhang, X., et al. (2011). Identification of an adenylyl cyclase
inhibitor for treating neuropathic and inflammatory pain. Sci. Transl. Med. 3,
65ra3.
Watabiki, T., Kiso, T., Kuramochi, T., Yonezawa, K., Tsuji, N., Kohara, A., Ka-
kimoto, S., Aoki, T., andMatsuoka, N. (2011). Amelioration of neuropathic pain
by novel transient receptor potential vanilloid 1 antagonist AS1928370 in rats
without hyperthermic effect. J. Pharmacol. Exp. Ther. 336, 743–750.
Waxman, S.G., Kocsis, J.D., and Black, J.A. (1994). Type III sodium channel
mRNA is expressed in embryonic but not adult spinal sensory neurons, and
is reexpressed following axotomy. J. Neurophysiol. 72, 466–470.
Weller, K., Reeh, P.W., and Sauer, S.K. (2011). TRPV1, TRPA1, and CB1 in the
isolated vagus nerve—axonal chemosensitivity and control of neuropeptide
release. Neuropeptides 45, 391–400.
Woolf, C.J. (1983). Evidence for a central component of post-injury pain hyper-
sensitivity. Nature 306, 686–688.
Woolf, C.J. (2011). Central sensitization: implications for the diagnosis and
treatment of pain. Pain 152 (3, Suppl), S2–S15.
Woolf, C.J., and Ma, Q. (2007). Nociceptors—noxious stimulus detectors.
Neuron 55, 353–364.
Woolf, C.J., and Thompson, S.W. (1991). The induction and maintenance of
central sensitization is dependent on N-methyl-D-aspartic acid receptor acti-
vation; implications for the treatment of post-injury pain hypersensitivity
states. Pain 44, 293–299.
Wu, G., Ringkamp, M., Murinson, B.B., Pogatzki, E.M., Hartke, T.V., Weera-
handi, H.M., Campbell, J.N., Griffin, J.W., and Meyer, R.A. (2002).Neuron 73, February 23, 2012 ª2012 Elsevier Inc. 651
Neuron
ReviewDegeneration of myelinated efferent fibers induces spontaneous activity in
uninjured C-fiber afferents. J. Neurosci. 22, 7746–7753.
Xiao,W.H., Zheng, H., Zheng, F.Y., Nuydens, R., Meert, T.F., and Bennett, G.J.
(2011). Mitochondrial abnormality in sensory, but not motor, axons in pacli-
taxel-evoked painful peripheral neuropathy in the rat. Neuroscience 199,
461–469.
Xie, R.G., Zheng, D.W., Xing, J.L., Zhang, X.J., Song, Y., Xie, Y.B., Kuang, F.,
Dong, H., You, S.W., Xu, H., and Hu, S.J. (2011). Blockade of persistent
sodium currents contributes to the riluzole-induced inhibition of spontaneous
activity and oscillations in injured DRG neurons. PLoS ONE 6, e18681.
Xu, G.Y., Li, G., Liu, N., and Huang, L.Y. (2011). Mechanisms underlying puri-
nergic P2X3 receptor-mediated mechanical allodynia induced in diabetic rats.
Mol. Pain 7, 60.652 Neuron 73, February 23, 2012 ª2012 Elsevier Inc.Yowtak, J., Lee, K.Y., Kim, H.Y., Wang, J., Kim, H.K., Chung, K., and Chung,
J.M. (2011). Reactive oxygen species contribute to neuropathic pain by
reducing spinal GABA release. Pain 152, 844–852.
Zhang, H., Nei, H., and Dougherty, P.M. (2010). A p38 mitogen-activated
protein kinase-dependent mechanism of disinhibition in spinal synaptic trans-
mission induced by tumor necrosis factor-alpha. J. Neurosci. 30, 12844–
12855.
Zhang, Y.H., Kays, J., Hodgdon, K.E., Sacktor, T.C., and Nicol, G.D. (2012).
Nerve growth factor enhances the excitability of rat sensory neurons through
activation of the atypical protein kinase C isoform, PKMz. J. Neurophysiol.
107, 315–335.
Zhao, J., O’Leary, M.E., and Chahine, M. (2011). Regulation of Na(v)1.6 and
Na(v)1.8 peripheral nerve Na(+) channels by auxiliary b-subunits. J. Neurophy-
siol. 106, 608–619.
